Key result
Early abciximab pre-treatment in STEMI patients was associated with a higher rate of pre-procedural TIMI 2-3 flow compared to administration after diagnostic angiography (45.9% vs 20.2%, P=0.0001).
Why the study?
Does early pre-treatment with abciximab improve pre-procedural coronary blood flow and reduce MACE in patients with STEMI undergoing primary PCI?
Observational (n=242)
No
Does early pre-treatment with abciximab improve pre-procedural coronary blood flow and reduce MACE in patients with STEMI undergoing primary PCI?
Absolute Event Rate: 45.9% vs 20.2%
p-value: p=0.0001
Early administration of abciximab before the catheterization laboratory in STEMI patients significantly improves pre-procedural coronary blood flow but does not significantly reduce 1-year MACE compared to administration after diagnostic angiography.
Early abciximab pre-treatment should not yet change STEMI practice; leaves open whether flow gains reduce MACE.
UNLABELLED: There is debate whether early treatment with GpIIb/IIIa inhibitors is of clinical benefit in primary percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI). This study explored the effects of early given abciximab on coronary blood flow and major adverse cardiac events (MACE) in patients with STEMI treated with primary PCI and adjunctive abciximab. We studied all consecutive patients from our catchment area with STEMI undergoing acute angiography with the intention of primary PCI during 2005. Abciximab was given as early pre-treatment before, (n = 133) or at the cath. lab. after a diagnostic angiography (n = 109). Pre-procedural TIMI 2-3 flow was observed in 45.9 % of patients in the early group versus 20.2 % in the cath. lab. group, P = 0.0001. Mortality rates were 3.8 % versus 3.7% inhospital and 8.3 % versus 7.3% at one year in the early respectively the cath. lab. group, both P = NS. The MACE rate (death, non fatal myocardial infarction, unplanned revascularization) at one year was 19.5 % (early group) and 26.6 % (cath. lab. group), P = 0.19. CONCLUSION: In this single centre registry study of unselected patients with STEMI early given abciximab was associated with a significantly higher rate of TIMI 2-3 flow compared to abciximab given after the acute angiography.
No takes yet. Share an insight, caveat, or question.
Tödt et al. (2010) conducted an observational in ST elevation myocardial infarction (STEMI) (n=242). Early abciximab pre-treatment vs. Abciximab given at the cath. lab. after diagnostic angiography was evaluated on Pre-procedural TIMI 2-3 flow (p=0.0001). Early abciximab pre-treatment in STEMI patients was associated with a higher rate of pre-procedural TIMI 2-3 flow compared to administration after diagnostic angiography (45.9% vs 20.2%, P=0.0001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: